Literature DB >> 16959493

Partial mitochondrial complex I inhibition induces oxidative damage and perturbs glutamate transport in primary retinal cultures. Relevance to Leber Hereditary Optic Neuropathy (LHON).

Simone Beretta1, John P M Wood, Barry Derham, Gessica Sala, Lucio Tremolizzo, Carlo Ferrarese, Neville N Osborne.   

Abstract

Leber Hereditary Optic Neuropathy (LHON) is a maternally inherited form of visual loss, due to selective degeneration of retinal ganglion cells. Despite the established aetiological association between LHON and mitochondrial DNA mutations affecting complex I of the electron transport chain, the pathophysiology of this disorder remains obscure. Primary rat retinal cultures were exposed to increasing concentrations of rotenone to titrate complex I inhibition. Neural cells were more sensitive than Müller glial cells to rotenone toxicity. Rotenone induced an increase in mitochondrial-derived free radicals and lipid peroxidation. Sodium-dependent glutamate uptake, which is mostly mediated by the glutamate transporter GLAST expressed by Müller glial cells, was reduced dose-dependently by rotenone with no changes in GLAST expression. Our findings suggest that complex I-derived free radicals and disruption of glutamate transport might represent key elements for explaining the selective retinal ganglion cell death in LHON.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959493     DOI: 10.1016/j.nbd.2006.07.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  24 in total

1.  Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Gislaine T Rezin; Daiane B Fraga; Juliana F Daufenbach; Giselli Scaini; Joana Benedet; Natália Rochi; Emílio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-09-28       Impact factor: 3.575

2.  [Hereditary optic atrophies].

Authors:  C M Poloschek; W A Lagrèze
Journal:  Ophthalmologe       Date:  2009-09       Impact factor: 1.059

3.  Therapeutic strategies for Leber's hereditary optic neuropathy: A current update.

Authors:  Nuri Gueven; Dharmesh Faldu
Journal:  Intractable Rare Dis Res       Date:  2013-11

4.  Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy.

Authors:  Julio C Rojas; Jung Lee; Joseph M John; F Gonzalez-Lima
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

Review 5.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

6.  Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat.

Authors:  Won-Seok Choi; Shane E Kruse; Richard D Palmiter; Zhengui Xia
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

7.  The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death.

Authors:  Boyoung Lee; Ruifeng Cao; Yun-Sik Choi; Hee-Yeon Cho; Alex D Rhee; Cyrus K Hah; Kari R Hoyt; Karl Obrietan
Journal:  J Neurochem       Date:  2009-01-28       Impact factor: 5.372

8.  Profiling of oxidative stress in patients with inborn errors of metabolism.

Authors:  Peter J Mc Guire; Aditya Parikh; George A Diaz
Journal:  Mol Genet Metab       Date:  2009-06-14       Impact factor: 4.797

9.  Ogg1 null mice exhibit age-associated loss of the nigrostriatal pathway and increased sensitivity to MPTP.

Authors:  Fernando Cardozo-Pelaez; Monica Sanchez-Contreras; Andrew B C Nevin
Journal:  Neurochem Int       Date:  2012-06-26       Impact factor: 3.921

10.  Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy.

Authors:  Julio C Rojas; Joseph M John; Jung Lee; F Gonzalez-Lima
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.